Because micafungin is generally well tolerated and appears to have limited interaction with
other drugs, it is a potential important agent in the treatment of invasive fungal
infections. Although micafungin is approved for the treatment of invasive candidiasis, dosing
guidelines for micafungin in (morbidly) obese patients are not available. Subsequently, the
pharmacokinetic profile of micafungin (as well as other echinocandins) in this specific
patient population is still largely unknown.
To build a valid pharmacokinetic model, obese patients with a BMI ≥ 40 undergoing endoscopic
gastric bypass surgery will receive a single dose of 100 mg or 200mg micafungin (besides
standard anti-bacterial prophylaxis) and samples for a pharmacokinetic curve will be taken.
These PK-values can then be compared to the PK in a normal-weight group which will receive
100mg micafungin